Stockscreener 앱 받기
9.39
2.07%
0.19
시간 외 거래:
9.02
-0.37
-3.94%
전일 마감가:
$9.20
열려 있는:
$9.22
하루 거래량:
3.01M
Relative Volume:
0.85
시가총액:
$1.04B
수익:
$631.73M
순이익/손실:
$-239.78M
주가수익비율:
-4.6485
EPS:
-2.02
순현금흐름:
$-33.45M
1주 성능:
+7.07%
1개월 성능:
+16.94%
6개월 성능:
-29.61%
1년 성능:
-63.31%
1일 변동 폭
$8.95
$9.42
1주일 범위
$8.70
$9.79
52주 변동 폭
$6.78
$25.65
10X 제노믹스 Stock (TXG) Company Profile
명칭
10 X Genomics Inc
전화
(925) 401-7300
주소
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
TXG을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
9.39 | 1.08B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
242.78 | 38.63B | 2.75B | 714.14M | 1.09B | 4.33 |
|
TEM
Tempus Ai Inc
|
65.49 | 10.62B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
98.23 | 7.82B | 1.15B | 96.70M | -161.99M | 1.09 |
|
DOCS
Doximity Inc
|
52.56 | 11.11B | 550.17M | 201.35M | 232.07M | 1.00 |
|
WAY
Waystar Holding Corp
|
39.34 | 6.92B | 906.14M | -52.62M | 89.62M | -0.3621 |
10X 제노믹스 Stock (TXG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-10 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-05-01 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-10 | 개시 | Barclays | Overweight |
| 2023-03-31 | 개시 | Stephens | Overweight |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-08-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-07-25 | 개시 | Canaccord Genuity | Buy |
| 2022-07-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-14 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-15 | 개시 | William Blair | Outperform |
| 2020-12-02 | 개시 | Goldman | Neutral |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-07-10 | 개시 | Stifel | Buy |
| 2020-03-05 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-07 | 개시 | BofA/Merrill | Buy |
| 2019-10-07 | 개시 | Cowen | Outperform |
| 2019-10-07 | 개시 | JP Morgan | Overweight |
| 2019-09-24 | 개시 | Evercore ISI | Outperform |
모두보기
10X 제노믹스 주식(TXG)의 최신 뉴스
'Shooting ourselves in the foot': Trump administration cuts force East Bay’s 10x Genomics into layoffs - The Business Journals
NanoString to pay 10x Genomics $68m in global settlement - Life Sciences Intellectual Property Review
10x Genomics reaches settlement with Bruker - Medical Buyer
Stifel Financial Corp Raises Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - Defense World
UBS Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $12.00 - Defense World
10x Genomics Reaches $68 Million Patent Settlement With Bruker - marketscreener.com
10x Genomics Settles Litigation with Bruker Corporation - TipRanks
10x Genomics settles patent dispute with Bruker for $68 million - Investing.com
10x Genomics Wins Massive $68M Settlement Plus Royalties in Major Patent Battle with Bruker - Stock Titan
All Ongoing Lawsuits Between Bruker And 10X Genomics To Be Withdrawn - marketscreener.com
Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96 - simplywall.st
10x Genomics (TXG) Price Target Reduced by UBS Amid Funding Chal - GuruFocus
Fierce Biotech Layoff Tracker 2025: Allogene cuts 28% of staff; Kyverna trims workforce by 16% - Fierce Biotech
10x Genomics, Bruker Strike Deal After $31M Patent Verdict - Law360
10x Genomics (TXG) Sees Price Target Lowered by UBS | TXG Stock News - GuruFocus
UPC battle between 10x Genomics and Curio Bioscience moves to next stage - JUVE Patent
UBS Adjusts Price Target on 10x Genomics to $12 From $14, Maintains Neutral Rating - marketscreener.com
Canaccord Adjusts 10x Genomics (TXG) Price Target Citing Market Uncertainty | TXG Stock News - GuruFocus
10x Genomics (NASDAQ:TXG) Price Target Lowered to $6.50 at The Goldman Sachs Group - Defense World
10x Genomics (NASDAQ:TXG) Price Target Cut to $15.00 by Analysts at Canaccord Genuity Group - Defense World
10x Genomics (TXG) Price Target Lowered by Canaccord Genuity | T - GuruFocus
Analyst Expectations For 10x Genomics's Future - Benzinga
JPMorgan Chase & Co. Cuts 10x Genomics (NASDAQ:TXG) Price Target to $9.00 - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Just Reported Earnings, And Analysts Cut Their Target Price - Yahoo Finance
10x Genomics (NASDAQ:TXG) Shares Gap Up – Time to Buy? - Defense World
10x Genomics (NASDAQ:TXG) Receives Sell (E+) Rating from Weiss Ratings - Defense World
10x Genomics First Quarter 2025 Earnings: Beats Expectations - simplywall.st
30,005 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by Raymond James Financial Inc. - Defense World
10x Genomics, Inc. (NASDAQ:TXG) Q1 2025 Earnings Call Transcript - Insider Monkey
JPMorgan Adjusts Price Target for 10x Genomics (TXG) Amid Market Concerns | TXG Stock News - GuruFocus
10x Genomics (TXG) Price Target Lowered to $9 by JP Morgan | TXG Stock News - GuruFocus
10x Genomics (TXG) Faces Price Target Reduction Amid Uncertain O - GuruFocus
Stifel Adjusts 10x Genomics (TXG) Price Target Amid Funding Conc - GuruFocus
Deutsche Bank Adjusts Price Target on 10x Genomics to $10 From $16, Maintains Hold Rating - marketscreener.com
Stifel Adjusts 10x Genomics (TXG) Price Target Amid Funding Concerns | TXG Stock News - GuruFocus
10x Genomics (TXG) Faces Price Target Reduction Amid Uncertain Outlook | TXG Stock News - GuruFocus
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigat - GuruFocus
10x Genomics (NASDAQ:TXG) adds US$65m to market cap in the past 7 days, though investors from five years ago are still down 89% - simplywall.st
10x Genomics, Inc. SEC 10-Q Report - TradingView
10x Genomics Reports First Quarter 2025 Financial Results - BioSpace
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives - GuruFocus
10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance - Benzinga
10x Genomics: Q1 Earnings Snapshot - CTPost
Compared to Estimates, 10x Genomics (TXG) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
10x Genomics’s (NASDAQ:TXG) Q1: Strong Sales But Quarterly Revenue Guidance Significantly Misses Expectations - Yahoo Finance
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
10x Genomics Announces Workforce Reduction to Cut Costs - TipRanks
10x Genomics Inc Q1 2025 Earnings: EPS of -$0.28 Beats Estimate, Revenue Surges to $154.9 Million - GuruFocus
Earnings Flash (TXG) 10x Genomics Posts Q1 Loss $-0.28 Per Share, vs. FactSet Est of $-0.47 - marketscreener.com
10x Genomics (NASDAQ:TXG) shareholders have endured a 90% loss from investing in the stock five years ago - Yahoo Finance
10X 제노믹스 (TXG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10X 제노믹스 주식 (TXG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Feb 28 '25 |
Sale |
10.63 |
7,942 |
84,393 |
871,540 |
0.94%
자본화:
|
볼륨(24시간):